Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
5
Bullish
5
Bearish
7
Neutral
5
Bullish
34
Bearish
3
Neutral
0
Bullish
29
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q3 FY26
Corona Remedies Ltd (CORONA) is currently trading at 2,166.90 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
CORONA Remedies Limited is an India-focused pharmaceutical manufacturer and marketer operating across women’s healthcare, cardio‑metabolic, pain management, urology and other therapies, with manufacturing sites in Solan and Ahmedabad and a recently commissioned Europe‑GMP hormonal facility aimed at domestic and export markets. The company reported a strong Q1 FY27 performance with consolidated revenue growth of 21.9% year‑on‑year and India business growth of 22.7%, materially outpacing the IPM growth of 11.6%, driven by a mix of volume, price increases and new product introductions. CORONA has deepened its chronic and semi‑chronic franchise, which now represents ~73.4% of the portfolio, and climbed to 26th position in IPM while ranking top‑5 in Women’s Healthcare and Pain Management, reflecting focused brand and specialist engagement strategies. Strategic investments include a ~INR130 crore EU‑GMP hormonal plant, acquisitions of multiple brands (Bayer‑Zydus portfolio, Wokadine, Myoril), and a ~31% stake in La Chandra Pharma Lab for API backward integration, positioning CORONA for higher domestic scale and emerging export traction over FY28–29.
Over the past 52 weeks, Corona Remedies Ltd has traded between a low of ₹1,336.95 and a high of ₹2,285.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Corona Remedies Ltd has a market capitalization of approximately 13,547.27. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Corona Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 68.07 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 13,547.27 Cr, Corona Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Corona Remedies Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Corona Remedies Ltd is 68.07. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The board is scheduled to meet on July 31, 2026 to approve the unaudited financial results for Q1 FY27 (quarter ended June 30, 2026).
The filing states India business revenue grew 17.18% in FY 2025-26 versus IPM growth of 8.59%.
Q3 FY26 revenue from operations was INR 342.42 crore (+15% YoY) and adjusted PAT was INR 55.56 crore (+23.7% YoY), excluding a one-time statutory impact.
Discovery themes featuring this stock
CORONA Remedies Limited is an India-focused pharmaceutical manufacturer and marketer operating across women’s healthcare, cardio‑metabolic, pain management, urology and other therapies, with manufacturing sites in Solan and Ahmedabad and a recently commissioned Europe‑GMP hormonal facility aimed at domestic and export markets.
The company reported a strong Q1 FY27 performance with consolidated revenue growth of 21.9% year‑on‑year and India business growth of 22.7%, materially outpacing the IPM growth of 11.6%, driven by a mix of volume, price increases and new product introductions.
CORONA has deepened its chronic and semi‑chronic franchise, which now represents ~73.4% of the portfolio, and climbed to 26th position in IPM while ranking top‑5 in Women’s Healthcare and Pain Management, reflecting focused brand and specialist engagement strategies.
Strategic investments include a ~INR130 crore EU‑GMP hormonal plant, acquisitions of multiple brands (Bayer‑Zydus portfolio, Wokadine, Myoril), and a ~31% stake in La Chandra Pharma Lab for API backward integration, positioning CORONA for higher domestic scale and emerging export traction over FY28–29.
Pharmaceuticals & Biotechnology
Pharmaceuticals
13,547 Cr
Low Risk
68.1
37.0
2.1
18.1
2,285.00
1,336.95
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
782.50 | 15,453 Cr | 15.24 | 1.47 | 0.58 | 15.38 | 15.37 | 9.16 | ||
926.80 | 15,012 Cr | 42.72 | 2.12 | 0.53 | 5.62 | 6.41 | 2.26 | ||
306.25 | 14,279 Cr | 27.39 | 4.72 | 0.29 | 13.82 | 17.37 | 13.50 | ||
2166.90 | 13,547 Cr | 68.07 | 18.14 | 0.45 | 24.79 | 27.13 | 16.52 | ||
1245.00 | 12,867 Cr | 46.05 | 6.20 | 0.61 | 13.61 | 18.02 | 12.01 | ||
1066.70 | 12,774 Cr | 67.72 | 13.34 | 0.00 | 19.67 | 21.94 | 14.20 | ||
735.00 | 11,664 Cr | 39.85 | 3.52 | 0.39 | 7.70 | 10.95 | 5.37 | ||
| Median: 7 Co. | — | 926.80 | 13,547 Cr | 42.72 | 4.72 | 0.45 | 13.82 | 17.37 | 12.01 |
